E-cadherin gene polymorphisms in asthma patients using inhaled corticosteroids Source: Eur Respir J 2011; 38: 1044-1052 Year: 2011
Effect of switching from high-dose inhaled corticosteroid (ICS) to low-dose ICS plus an inhaled long-acting β2 -agonist on asthma control, airway inflammation and remodeling, and gene expression in airway epithelial cells Source: Eur Respir J 2003; 22: Suppl. 45, 35s Year: 2003
Changes in objective markers following inhaled corticosteroids (ICS) in asthmatics with airway hyperresponsiveness (AHR) to mannitol Source: International Congress 2019 – Airway physiology Year: 2019
Reducing the dose of inhaled corticosteroids (ICS) under therapy with montelukast in stable asthma: effects on lung function and inflammation Source: Eur Respir J 2001; 18: Suppl. 33, 261s Year: 2001
COPD: Inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) combination and oxygen saturation (OS) in patients (pts) with different plasma surfactant protein D (SP-D) level Source: International Congress 2015 – COPD: notable points Year: 2015
Dose reduction of inhaled corticosteroids under concomitant medication with montelukast in patients with asthma Source: Eur Respir J 2002; 20: 1080-1087 Year: 2002
Effects of intervention with high-dose inhaled corticosteroids on airway remodelling in diagnosed genetic variants of IL13 with asthma Source: Annual Congress 2010 - Asthma: clinical aspects and treatment Year: 2010
Platelet activating factor receptor (PAFr) expression is increased in airways of COPD patients but is not attenuated by inhaled corticosteroid (ICS) Source: Annual Congress 2013 –COPD: new markers of diseases Year: 2013
Inhaled corticosteroids and growth of airway function in asthmatic children Source: Eur Respir J 2004; 23: 861-868 Year: 2004
Effects of salmeterol/fluticasone propionate (SFC) on airway inflammation in induced sputum in COPD Source: Annual Congress 2005 - Effects of anti-inflammatory drugs on COPD Year: 2005
Fluticasone furoate, a novel inhaled corticosteroid (ICS), provides sustained protection against amp airway hyperresponsiveness (AHR) in mild asthma Source: Annual Congress 2009 - New drugs for airways disease Year: 2009
Salmeterol/fluticasone propionate combination (SFC) improves airways hyperresponsiveness (AHR), lung function and symptoms in adult patients with mild asthma Source: Eur Respir J 2004; 24: Suppl. 48, 262s Year: 2004
Inhaled corticosteroid (ICS) induced metabolome changes in asthmatics. Source: Virtual Congress 2020 – Cutting edge science: novel molecules and mechanisms of airway diseases Year: 2020
Airway remodelling augmented in patients with asthma COPD overlap (ACO) compared to asthma and COPD. Source: Virtual Congress 2021 – Novel insights into the pathogenesis of chronic lung diseases Year: 2021
Effects of low dose inhaled theophylline (ADC4022) co-administered with budesonide on inflammatory markers, lung function, and quality of life in COPD patients Source: Annual Congress 2009 - New drugs for airways disease Year: 2009
Comparison of fluticasone propionate + salmeterol (FP+S) and montelukast (MK) on bronchial reactivity (BR), pulmonary function (PF) and clinical outcome in children with mild asthma Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009
Severe therapy resistant asthma Source: ISSN=1025-448x, ISBN=1-904097-26-x, page=312 Year: 2003
Treatment with inhaled steroids in patients with symptoms suggestive of asthma but with normal lung function Source: Eur Respir J 2008; 32: 989-996 Year: 2008
Reduced risk for asthma exacerbations in pediatric patients receiving salmeterol plus inhaled corticosteroids (ICS) vs. ICS alone Source: Eur Respir J 2004; 24: Suppl. 48, 308s Year: 2004
Is GLCCI1 associated with response to inhaled corticosteroids in asthma patients? Source: Annual Congress 2012 - Gene-environment treatment and asthma Year: 2012